Oncotarget
GRP-R and FAK expressions correlate to neuroblastoma malignancy and GRP-induced FAK activation. More intense immunofluorescence of FAK and GRP-R were observed in BE(2)-C cells when compared to SK-N-SH cells. The figure of BE(2)-C was digitally enhanced for the cover of Oncotarget. See Lee et al.
The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer |
https://doi.org/10.18632/oncotarget.771 Nicolas Floc'h, and Cory Abate-Shen |
1483-1484 |
PDF | HTML | How to cite | Order a Reprint |
PI3Kβ downstream of GPCRs – crucial partners in oncogenesis |
https://doi.org/10.18632/oncotarget.787 Hashem A Dbouk, Oscar Vadas, Roger L Williams, and Jonathan M Backer |
1485-1486 |
PDF | HTML | How to cite | Order a Reprint |
Endotrophin – Linking Obesity with Aggressive Tumor Growth |
https://doi.org/10.18632/oncotarget.796 Jiyoung Park, and Philipp E. Scherer |
1487-1488 |
PDF | HTML | How to cite | Order a Reprint |
Attacking MALT1 for ABC-DLBCL therapy |
https://doi.org/10.18632/oncotarget.794 Daniel Krappmann |
1489-1490 |
PDF | HTML | How to cite | Order a Reprint |
mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio |
https://doi.org/10.18632/oncotarget.799 Tommy Alain, Nahum Sonenberg, and Ivan Topisirovic |
1491-1492 |
PDF | HTML | How to cite | Order a Reprint |
Targeting Lymphomas Through MALT1 Inhibition |
https://doi.org/10.18632/oncotarget.819 Lorena Fontan, and Ari Melnick |
1493-1494 |
PDF | HTML | How to cite | Order a Reprint |
PU.1 is a tumor suppressor for B cell malignancies |
https://doi.org/10.18632/oncotarget.800 Yutaka Okuno, and Hiromichi Yuki |
1495-1496 |
PDF | HTML | How to cite | Order a Reprint |
Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses |
https://doi.org/10.18632/oncotarget.792 Roheena Z Panni, David C Linehan, and David G DeNardo |
1497-1498 |
PDF | HTML | How to cite | Order a Reprint |
Coordinate PI3K pathway and Bcl-2 family disruption in AML |
https://doi.org/10.18632/oncotarget.809 Prithviraj Bose, Mohamed Rahmani, and Steven Grant |
1499-1500 |
PDF | HTML | How to cite | Order a Reprint |
Targeting Tumor Stroma: Exploiting Apoptotic Priming |
https://doi.org/10.18632/oncotarget.830 Joachim C. Mertens, and and Gregory J. Gores |
1501-1502 |
PDF | HTML | How to cite | Order a Reprint |
The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome |
https://doi.org/10.18632/oncotarget.780 Arnold J. Levine, and Benjamin Greenbaum |
1503-1504 |
PDF | HTML | How to cite | Order a Reprint |
Advances in Targeting Signal Transduction Pathways. |
https://doi.org/10.18632/oncotarget.802 James Andrew McCubrey, Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis, Stephen L Abrams, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B D'Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello, and Zoya N Demidenko |
1505-1521 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes |
https://doi.org/10.18632/oncotarget.889 Albert E. Berman, Olga V. Leontieva, Venkatesh Natarajan, James A. McCubrey, Zoya N. Demidenko, and Mikhail A. Nikiforov |
1522-1532 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 |
https://doi.org/10.18632/oncotarget.747 Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, Yoshiji Hantani, Nobuyuki Okajima, Toshiyuki Sakai, Yoshihiro Watanabe, and Motonao Nakamura |
1533-1545 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer |
https://doi.org/10.18632/oncotarget.667 David W Chan, Celia SL Mak, Thomas HY Leung, Karen KL Chan, and Hextan YS Ngan |
1546-1556 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib |
https://doi.org/10.18632/oncotarget.692 Ophelie Cassuto, Maeva Dufies, Arnaud Jacquel, Alexandre Puissant, Clemence Ginet, Amine Hamouda, Frederic Luciano, Guillaume Robert, Jean-Michel Karsenti, Laurence Legros, Jill Patrice Cassuto, Pascal Lenain, and Patrick Auberger |
1557-1565 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes |
https://doi.org/10.18632/oncotarget.716 Filip Janku, Jennifer J. Wheler, Aung Naing, Vanda M. T. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido-Laguna, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, and Razelle Kurzrock |
1566-1575 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
FAK is a critical regulator of neuroblastoma liver metastasis |
https://doi.org/10.18632/oncotarget.732 Sora Lee, Jingbo Qiao, Pritha Paul, Kathleen L. O’Connor, Mark Evers, and Dai H. Chung |
1576-1587 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) |
https://doi.org/10.18632/oncotarget.733 Harald Herrmann, Katharina Blatt, Junwei Shi, Karoline V. Gleixner, Sabine Cerny-Reiterer, Leonhard Müllauer, Christopher R. Vakoc, Wolfgang R. Sperr, Hans-Peter Horny, James E. Bradner, Johannes Zuber, and Peter Valent |
1588-1599 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment |
https://doi.org/10.18632/oncotarget.742 Sílvia Cufí, Alejandro Vazquez-Martin, Ceistina Oliveras-Ferraros, Bruna Corominas-Faja, Ander Urruticoechea, Begoña Martin-Castillo, and Javier A Menendez |
1600-1614 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
https://doi.org/10.18632/oncotarget.762 Francesca Chiarini, Annalisa Lonetti, Gabriella Teti, Ester Orsini, Daniela Bressanin, Alessandra Cappellini, Francesca Ricci, Pier Luigi Tazzari, Andrea Ognibene, Mirella Falconi, Pasqualepaolo Pagliaro, Ilaria Iacobucci, Giovanni Martinelli, Sergio Amadori, James A McCubrey, and Alberto M Martelli |
1615-1628 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer |
https://doi.org/10.18632/oncotarget.790 Suyoun Chung, Hanae Suzuki, Takashi Miyamoto, Naofumi Takamatsu, Ayako Tatsuguchi, Koji Ueda, Kyoko Kijima, Yusuke Nakamura, and Yo Matsuo |
1629-1640 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Lin28b Promotes Head and Neck Cancer Progression via Modulation of the Insulin-Like Growth Factor Survival Pathway |
https://doi.org/10.18632/oncotarget.785 Nehad M Alajez, Wei Shi, Dennis Wong, Michelle Lenarduzzi, John Waldron, Ilan Weinreb, and Fei-Fei Liu |
1641-1652 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 |
https://doi.org/10.18632/oncotarget.810 Haoran Li, and Burton B Yang |
1653-1668 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia |
https://doi.org/10.18632/oncotarget.806 Wolfgang Warsch, Eva Grundschober, Angelika Berger, Lars Gille, Sabine Cerny-Reiterer, Anca-Sarmiza Tigan, Andrea Hoelbl-Kovacic, Peter Valent, Richard Moriggl, and Veronika Sexl |
1669-1687 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway |
https://doi.org/10.18632/oncotarget.791 Guillaume Robert, Valérie Jullian, Arnaud Jacquel, Clémence Ginet, Maeva Dufies, Stephanie Torino, Anaïs Pottier, Frederic Peyrade, Sophie Tartare-Deckert, Geneviève Bourdy, Eric Deharo, and Patrick Auberger |
1688-1699 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Gene expression-based risk score in diffuse large B-cell lymphoma |
https://doi.org/10.18632/oncotarget.807 Caroline Bret, Bernard Klein, and Jérôme Moreaux |
1700-1710 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI’s provocative questions |
https://doi.org/10.18632/oncotarget.890 Mikhail V. Blagosklonny |
1711-1724 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC